Project Grant R41AG094359
Award Date 9/22/25
Completion Date 3/22/26
Dollars Obligated $475K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
South Dakota, USA
Similar Awards
- This Project Grant award of $252,124 from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) is focused on drug discovery targeting the amyloid precursor protein transmembrane domain to selectively reduce amyloid production for the treatment of Alzheimer's disease. The 2-year project aims to carry out structure-activity relationship (SAR) analysis and lead optimization of a compound (C1) in Aim 1, and then conduct in vivo pharmacokinetic and...
- This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
- The National Institute on Aging (NIA) awarded a $254,896 Project Grant under its Aging Research program (CFDA 93.866) to Glial Therapeutics, LLC, a for-profit company located in Boston, MA. The grant aims to test whether pharmacological inhibition of the integrin αVβ8 (ITGB8) can restore microglia-astrocyte responses as a therapy for Alzheimer's disease (AD). Specifically, the project will evaluate the use of a new humanized monoclonal antibody, ADWA11, which is currently in Phase 1 clinical...
- This Project Grant award from the National Institute on Aging's (NIA) Aging Research Federal Grant Program (CFDA 93.866) is supporting Advantage Therapeutics, Inc. to conduct IND-enabling studies on a small molecule drug candidate that is disease-modifying for Alzheimer's disease. The goal is to advance this low-cost, long-acting treatment option through preclinical and IND-enabling activities. The $1,249,957 award runs from September 2025 through May 2027 and aims to develop a therapy that...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
- The National Institute on Aging (NIA) awarded a $349,605 Project Grant under the Aging Research federal grant program (CFDA 93.866) to Stress Therapeutics, Inc., a San Diego-based for-profit company, to advance the lead optimization of a novel therapeutic candidate for treating Alzheimer's disease (AD). The project aims to develop a first-in-class treatment targeting the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, a key pathogenic driver of AD progression. The funding will...
- The National Institute on Aging (NIA) awarded a $506,061 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to Redwood Neuro Inc. of Irvine, CA. The grant, awarded on September 15, 2025, aims to develop the SIMOLISA platform, an innovative and cost-effective technology designed to enable earlier and more sensitive detection of Alzheimer's disease biomarkers like p-tau proteins and β-amyloid through a blood-based assay. Unlike conventional systems that require expensive...
- The National Institute on Aging (NIA) awarded a $949,062 Project Grant (CFDA 93.866) to Somatoceutics LLC to develop a non-toxic, peptide-based nanomaterial (SMC-101 nanotubes) for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and other dementias. The objectives are to optimize the nanotubes for drug-loading and transcytosis across a blood-brain barrier model in vitro, and then evaluate their toxicity and ability to deliver the drug galantamine to the central...
- This $499,588 Project Grant was awarded on September 22, 2025 by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to Exqor Technologies Inc., a small disadvantaged business located in Boston, MA. The goal of this project is to develop non-radioactive nanoprobes that can be used for magnetic resonance imaging (MRI) of the tropomyosin receptor kinase B (TrkB) protein, which is implicated in the pathology of Alzheimer's disease (AD). The...